MADRID, 20 Nov. (EUROPA PRESS) -
Atrys Health has sold 100% of its compliance subsidiary Conversia for a total amount of 55 million euros, as the company reported this Monday to the National Securities Market Commission (CNMV).
In this sense, the company has received a binding offer for the sale of the remaining 75.01% of Conversia's shares to the company Arraigo Midco, controlled by Arraigo NW Segundo, for 35 million euros.
Specifically, the current offer for 75.01% of Conversia's shares, together with the sale of 24.99% of the company carried out on December 22, 2022, will allow Atrys to obtain a total amount of 55 million of euros for the sale of 100% of Conversia.
This divestment, as the firm has detailed, is part of Atrys' strategic plan "which focuses its activity on the 'Precision Medicine' and 'Prevention Medicine' business segments."
The funds obtained from the sale of 75.01% of Conversia will be used to reduce the financial debt of the Atrys group.
The company has highlighted that the completion of the operation is subject to the execution of the corresponding contractual agreements common in this type of operations and it is estimated that it will be executed before the end of fiscal year 2023.
On the other hand, the firm has also sent this Monday to the CNMV the call for its extraordinary general meeting of shareholders for next December 21, 2023, in which it will agree to the issuance of convertible bonds for a maximum amount of up to 25 million euros.
The firm has assured that with the two previous operations a total of 43 million of Atrys' financial debt will be amortized.
In addition, Atrys has updated its earnings forecast as a result of Conversia's departure from the perimeter and has highlighted that it expects to achieve a turnover of between 202 and 208 million euros and a gross operating result (Ebitda) of between 45 and 46 millions of euros.
In the words of the CEO of Atrys, Santiago de Torres, "the completion of the sale of Conversia will drive the organic growth of the strategic areas of our business, which range from early diagnosis, precision medical treatment and preventive medicine." .
